On March 1, 2021 EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"), a clinical stage precision medicine company reported that its proprietary Acoustic Cluster Therapy (ACT) platform technology for targeted therapeutic enhancement will be the subject of a presentation at the forthcoming ESMO (Free ESMO Whitepaper) Targeted Anticancer Therapies (TAT) Virtual Congress 2021 (Press release, Exact Therapeutics, MAR 1, 2021, View Source [SID1234578278]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ESMO (Free ESMO Whitepaper) Targeted Anticancer Therapies Virtual Congress 2021 is set to offer participants a glimpse of the future of targeted anticancer therapies and is the premier international meeting focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development.
The presentation will take place on March 1st 2021 and will focus on the background and rationale of ACT, preclinical study data and the ongoing Phase I evaluation. The Phase I ACTIVATE study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ACT when co-administered with standard of care chemotherapy in patients with metastatic colorectal cancer.
Title: Acoustic cluster therapy (ACT) as a mechanism of increasing drug delivery: Phase I experience (ID50)
Presenting Author: Prof Udai Banerji, NIHR Professor of Molecular Cancer Pharmacology at The Institute of Cancer Research, London, and Honorary Consultant in Medical Oncology, Royal Marsden Hospital NHS Foundation Trust.
Session: (Educational) Nothing is undruggable! (ID19)
Date/Time: Monday 1st March 2021/ 13.00-13.15
The Targeted Anticancer Therapies 2021 Virtual Congress 2021 will bring together experts in anticancer drug discovery and clinical development, translational scientists, and regulators in a unique forum to highlight recent advances and new data, whilst promoting collaboration and knowledge-sharing in a bench-to-bedside approach.The TAT meeting is a meeting focused on early clinical trials and has been described as ‘The home of phase I in oncology’. This meeting will be entirely dedicated to improving the conduct of early anti-cancer clinical trials, with presentations, discussions and educational reviews and workshops highlighting emerging pre-clinical and clinical data, as well as defining optimal methodologies for early clinical trials
About ACT
• ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
• ACT is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
• Initial focus of the company is oncology, however the ACT platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.